Incyte Corporation $INCY Stake Increased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 36.8% during the 3rd quarter, Holdings Channel reports. The firm owned 975,726 shares of the biopharmaceutical company’s stock after buying an additional 262,372 shares during the period. Pictet Asset Management Holding SA’s holdings in Incyte were worth $118,984,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Incyte in the 2nd quarter worth approximately $2,044,189,000. Wellington Management Group LLP boosted its stake in Incyte by 9.5% in the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock worth $405,321,000 after purchasing an additional 309,385 shares during the period. Dimensional Fund Advisors LP boosted its stake in Incyte by 10.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock worth $185,873,000 after purchasing an additional 187,354 shares during the period. Legal & General Group Plc purchased a new stake in Incyte during the 2nd quarter valued at approximately $182,054,000. Finally, Pacer Advisors Inc. grew its holdings in Incyte by 2.2% during the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock valued at $163,869,000 after buying an additional 37,790 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Incyte Stock Performance

Shares of INCY opened at $119.65 on Monday. The company has a market cap of $24.39 billion, a P/E ratio of 63.64, a P/E/G ratio of 4.36 and a beta of 0.78. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60. The company’s fifty day simple moving average is $119.62 and its 200-day simple moving average is $108.51.

Incyte (NASDAQ:INCY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same period last year, the company posted $2.26 earnings per share. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. Analysts predict that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on INCY. Canaccord Genuity Group started coverage on shares of Incyte in a research report on Thursday, August 20th. They set a “buy” rating and a $152.00 price objective on the stock. Weiss Ratings lowered shares of Incyte from a “buy (b)” rating to a “hold (c)” rating in a research report on Wednesday. Barclays upped their target price on shares of Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Leerink Partners cut their target price on shares of Incyte from $154.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Benchmark reiterated a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. Eleven equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $132.86.

Insider Buying and Selling at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the sale, the insider directly owned 183,200 shares in the company, valued at $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the transaction, the insider directly owned 21,126 shares in the company, valued at $2,513,148.96. This represents a 2.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 14,053 shares of company stock valued at $1,726,519. Corporate insiders own 16.20% of the company’s stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Incyte Profile

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.